The age bracket 35–37 sits at a clinically significant inflection point in fertility medicine. IVF success rates are meaningfully lower than at 30–32, but still substantially higher than at 40+. NHS eligibility windows are either already closing or about to close, depending on the ICB. And the decisions made about timing and treatment in this age range have real implications for outcomes.

This guide focuses specifically on what the evidence shows for patients in this age group — rather than extrapolating from broader data that doesn't reflect your situation.

What the Numbers Say

HFEA data for patients aged 35–37 using their own eggs:

  • Live birth rate per embryo transfer: approximately 25–30%
  • This compares to 32–38% for patients under 35 and 18–22% for patients aged 38–39
  • Per egg collected (a more complete measure), rates are lower — reflecting cycles where collection or fertilisation doesn't produce a transferable embryo

What this means in practice: The majority of 35–37 patients who undergo a single IVF cycle will not achieve a live birth from that cycle. Over two or three cycles, cumulative success rates rise substantially — approximately 50–65% over three cycles, depending on ovarian reserve and individual factors.

For a full breakdown of how to read HFEA data, see HFEA success rates explained.

Why 35–37 Is a Pivotal Window

Egg quality is still meaningfully good — but declining. The chromosomal abnormality rate per egg at 35–37 is approximately 30–40%, rising steeply from 38 onwards. This is why success rates decline so sharply from the late thirties: the same embryo that would implant at 34 is more likely to be aneuploid at 38.

Ovarian reserve is typically still adequate. AMH and AFC in the 35–37 range are generally sufficient for a stimulated cycle to produce a useful cohort of eggs. Reserve does decline with age, but most women in this age range are not yet facing the poor-response challenges common at 40+.

NHS eligibility is time-sensitive. Most ICBs have an upper age limit of 39–42 for NHS IVF, but require a period of trying before eligibility. If you are 36 and your ICB requires 2 years of trying before qualification, you may reach the eligibility criteria at 38 — still within the NHS window, but with meaningfully lower success rates than if treatment had started at 35. This is an argument for beginning the investigation process and GP referral discussion now rather than waiting.

NHS IVF at 35–37: Timing Matters

At 35, you technically have years until most NHS age thresholds close — but the referral and waiting list process takes time. Typical timeline from deciding to investigate to starting a first NHS IVF cycle: 12–24 months or more in many areas. If treatment doesn't start until 38 or 39, success rates will be lower than if it had started at 36.

If you have been trying for 12 months without success and are 35–37:

  • Ask your GP for a fertility investigation referral now — do not wait another 6 months
  • Check your ICB's specific eligibility criteria at nestie.co/nhs to confirm you qualify and understand any conditions
  • Consider getting an AMH test privately if your GP does not arrange one promptly — this will tell you whether the timeline feels urgent

Ovarian Reserve at 35–37

Most women in this age range have adequate ovarian reserve for IVF stimulation, but this varies. AMH can be below the expected range for age in some women in their mid-thirties — due to genetics, smoking history, prior ovarian surgery, or other factors.

An AMH below approximately 5 pmol/L at 35–37 suggests diminished reserve and changes the clinical picture — both for expected egg yield and for NHS eligibility (some ICBs have AMH lower limits that may affect access). For detail on what low AMH means in this age group, see low AMH and IVF.

Common Clinical Scenarios at 35–37

Unexplained infertility after 12–18 months of trying: This is the most common presenting situation. IVF is the most diagnostically informative and therapeutically effective treatment — it directly tests fertilisation capacity and embryo development in a way that IUI or continued natural conception does not.

Endometriosis: Moderate to severe endometriosis in this age range warrants IVF consideration rather than continued expectant management, given the time-sensitive nature of the fertility window. See endometriosis and IVF.

PCOS with anovulation: Where ovulation induction has not resulted in pregnancy after 6 ovulatory cycles, IVF is appropriate. PCOS patients in this age range generally have good outcomes with IVF. See PCOS and IVF.

Male factor: Mild to moderate male factor with adequate female fertility at 35–37 is a reason to consider IVF (with ICSI where indicated) rather than extended IUI attempts — time matters in this window.

Egg Freezing at 35–37

For women in this age range who are not currently trying to conceive but want to preserve options, egg freezing is more effective than at 40+ — but less effective than it would have been at 30–32.

Expected outcomes for eggs frozen at 35–37: per-egg live birth rates of approximately 5–8%, meaning 10–15 eggs frozen gives a cumulative chance of approximately 50–70% of one live birth if all eggs are eventually used.

Whether egg freezing is the right decision at 35–37 depends on circumstances — including the cost of the cycles, how many eggs are expected per cycle, and the specific life context. See egg freezing in the UK for a full analysis.

Frequently Asked Questions

Q: At 36, should I try IUI first or go straight to IVF?

A: This depends on your diagnosis. If there is a known reason for IVF (tubal factor, significant male factor, endometriosis), go directly. For unexplained infertility with time pressure, the argument for skipping IUI and going to IVF is stronger at 36 than at 32 — the per-cycle IVF success rate is higher than IUI, and each month matters more. See IUI vs IVF.

Q: My AMH is normal for my age. Does that mean IVF will definitely work?

A: A normal AMH is a good sign for expected egg yield per cycle, but it does not predict egg quality or IVF success. Aneuploidy rates at 35–37 are already meaningfully elevated, and even cycles with good egg numbers may not produce a euploid blastocyst for transfer. Normal AMH is reassuring about quantity; it says less about quality.

Q: Should I consider PGT-A at 36?

A: At 36, the aneuploidy rate per embryo is approximately 30–40% — meaningfully elevated but not as high as it will be at 40+. PGT-A at 36 is not universally recommended; the HFEA notes limited evidence of benefit for all patient groups. It may be most useful if you have multiple embryos and want to prioritise transfer order, or if you have had previous IVF failure or pregnancy loss. Discuss with your consultant. See preimplantation genetic testing.

Q: Will having one child already affect my NHS IVF eligibility at 36?

A: Yes, for most ICBs. Most NHS IVF policies require that neither partner has a living child from any relationship. This is one of the most common reasons people in their mid-thirties are denied NHS IVF despite otherwise qualifying. Private IVF is the realistic route for secondary infertility in this situation.

Q: How urgent is it to seek help at 35?

A: The most honest answer is: more urgent than at 30, and considerably less urgent than at 39. Each year from 35 brings a measurable decline in success rates. Seeking investigation after 12 months of trying is appropriate — and after 6 months if you are 35+. Waiting 2 years before investigating at 35 is not optimal.

This article is for information only and does not constitute medical advice. Success rates quoted are approximate and age-group averages; individual outcomes depend on many factors.